What is TLX's current stock price?

TLX (Telix Pharmaceuticals Limited) is currently trading at $9.47 with a market cap of $3.21B.

What sector is Telix Pharmaceuticals Limited in?

Telix Pharmaceuticals Limited (TLX) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is TLX a good stock to buy?

Analysts have a Buy consensus on TLX with a price target of $17.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

TLX Telix Pharmaceuticals Limited

Healthcare

$9.47-7.79%ClosedMarket Cap: $3.21B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

83.26

PEG

0.60

P/B

6.97

P/S

3.55

EV/EBITDA

132.54

DCF Value

$-182.76

FCF Yield

-1.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

50.8%

Operating Margin

2.1%

Net Margin

-0.9%

ROE

-2.1%

ROA

-0.6%

ROIC

1.8%

Financials

View All

Period	Revenue	Net Income	EPS
Q4 null	$620.4M	$-7.3M	$—
FY null	$1.21B	$-10.7M	$—
Q2 null	$593.1M	$-3.5M	$—
Q4 null	$594.2M	$38.2M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$17.00

Target (Median)

$17.00

Target Range

$17.00 - $17.00

0 Strong Buy5 Buy0 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-04-13

WedbushOutperform

2026-04-13

CitigroupBuy

2026-02-24

HC Wainwright & Co.Buy

2026-01-21

UBSBuy

2025-09-23

Trading Activity

Insider Trades

View All

Rivas Mariadirector:

SellMon May 18

Jellison William Rdirector:

SellMon May 18

GILL DAVID Ndirector:

SellMon May 18

Behrenbruch Christiandirector, officer: MD & Group CEO

BuyWed May 06

Behrenbruch Christiandirector, officer: MD & Group CEO

BuyWed May 06

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.65

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma. The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.

Peers

DYN